ATAI Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. It was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.
ATAI Life Sciences operates a technology-driven and decentralized platform intended to develop drugs for anxiety and depression treatment. The company's drugs are made of psilocybin mushroom that contains psychedelic prodrug compound which helps to disrupt the sorts of engrained brain activity patterns and alleviate anxiety in cancer patients, enabling people to live longer healthier and happier lives.